Cross-Sector entity
Of the tracked stories, 2 of 4 also mention Bayer, the most common co-covered peer. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 1 other category. We currently track 4 Cross-Sector stories that mention HMI-115, all published on March 25, 2026.
4 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Bayer, the most common co-covered peer. The clearest coverage concentration is clinical-trial: 2 of 4 stories, with the rest divided among 1 other category. We currently track 4 Cross-Sector stories that mention HMI-115, all published on March 25, 2026. Each carries 6.5 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HMI-115. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Source: manilatimes.net · prnewswire.com
